Study of SYH2062 Injection in Healthy Chinese Volunteers
ConditionHealthy Chinese Volunteers
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
About this trial
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of SYH2062 injection in healthy Chinese volunteers
Eligibility criteria
Qualifiers
Subjects must give informed consent before the trial, fully understand the content, process and possible adverse reactions, and voluntarily sign a written informed consent.
Age of 18 - 55 years (inclusive).
BMI: 19.0-26.0 kg/m² (inclusive), with a minimum weight of 50 kg (inclusive) for males and 45 kg (inclusive) for females.
Has Systolic blood pressure (SBP) ≥100 mmHg and <140 mmHg and diastolic blood pressure (DBP) ≥60 mmHg and <90 mmHg at screening;
Disqualifiers
None
Trial design
Treatments tested in this trial
- SYH2062 injection
- SYH2062-Matching placebo
Treatment groups
46 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov